Market commentators like to pigeonhole equity investors with simple terms such as active, passive, contrarian, value, growth or momentum. This makes things unnecessarily complicated as most people are investing for either value or growth.
Our approach is different. We are business-transformation investors focused on management and strategic change within good companies. We back strategies to make firms more relevant, profitable, cash-generative, consistent and more highly valued.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Healthy returns from medical devices
Convatec (LSE: CTEC) is a medical device and products company with a market value of £5 billion. It boasts large market shares in global ostomy, incontinence, diabetes and advanced wound care. After years of underinvestment and short-termism, new managers have restructured the business in the past five years and put customers and products at its heart.
Research and development (R&D) expenditure rose from 2% to 6% of revenue. The new product pipeline has never been better and has helped drive revenue growth from 2% in 2019 to 8% this year. The growth rates appear sustainable and are underpinning a margin recovery towards 25%.
Babcock International (LSE: BAB) is a £2.5 billion defence and engineering services business. Prior management for many years pursued an acquisition-led growth strategy that lacked capital and financial discipline, leading to cash-flow problems and balance sheet constraints. David Lockwood and David Mellors were appointed CEO and CFO respectively in 2020; both had backgrounds involving transforming firms in the defence and engineering industries. They undertook a systematic restructuring to focus on core services and businesses, the sale of non-core assets and an internal cost-saving and cash-flow management strategy. This repaired the balance sheet by reducing debt and improving working capital. It also provided money for reinvestment in core assets, leading to more focused growth. Sales expanded more quickly at higher margins and the long-term order book grew.
Team17 (Aim: TM17) is an Aim-listed independent games developer and publisher, with an established record and a strong brand. The shares have declined since Covid as the boom in gaming attracted capital into the sector and fuelled high valuations.
Again, there is new management with strong industry skills executing a more focused strategy around the deep and valuable back catalogue and first-party independent games growth. The balance sheet has a net cash balance of £50 million and the stock is on ten times earnings, with growth now recovering.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Families suffer £20,000 lost income growth – are you feeling the pinch?Average incomes for working age families have increased by just 7% in the past two decades, research suggests
-
How to achieve a secure retirement, as more retirees admit to struggling with debtTwenty-six percent of retirees now have unsecured debt – a sharp rise compared to two years ago – with many underestimating how much a typical retirement costs
-
Small UK industrial stocks are hidden gemsOpinion Ed Wielechowski of the Odyssean Investment Trust highlights three of his favourite British small-cap industrial stocks
-
Aurora Innovation is running on empty – is it overvalued?Aurora Innovation, a maker of self-driving trucks, may have promised far more than it can deliver
-
'Ride the recovery in emerging markets': Gustavo Medeiros of Ashmore Group tells MoneyWeekInterview What's the outlook for emerging markets? Gustavo Medeiros, head of research at Ashmore Group, gives his analysis and reviews progress in developing economies
-
What is the Enterprise Investment Scheme and should you have one?The Enterprise Investment Scheme is tax-efficient and potentially lucrative. Taking a chance on the scheme could trim your family’s IHT bill, says David Prosser
-
The alcohol industry is suffering as consumers sober up – is it still worth investing in the sector?Changing consumer tastes are rocking the alcohol industry, but the best players are adapting their strategies. Buy them while their shares are still cheap
-
A strange calm in creditCorporate bond markets remain remarkably relaxed, with yields that offer little compensation for risks
-
'The City's big bet on green finance fails to pay out'Opinion Insurers and banks are backing away from “green finance”, and there is not much sign of the green boom we were promised. That’s a problem for the City
-
Six top investment trusts for smaller stocksLiquidity constraints mean investment trusts are best placed to seize the juiciest opportunities
